Superworth

DexCom price to free cash flow DXCM

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Nov 3, 2026
22.7×
9-year median
146×
Against its 9-year history
6th
percentile: 0 is its lowest day, 100 its highest
9-year range
16.4× to 500×
Peer median
24.0×

DexCom's price to free cash flow is 22.7× as of Nov 3, 2026.

That is below its 9-year median of 146×, lower than on 94% of days in the last 9 years.

Over that time it ranged from 16.4× in May 2026 to 500× in Aug 2021.

The median for 9 medical device stocks of a similar size is 24.0×.

Price to free cash flow over time

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far22.8×16.4×26.8×
202524.8×20.2×65.0×
202458.6×38.5×105×
202395.9×63.4×171×
2022167×147×424×
2021373×120×500×
2020134×115×433×
2019392×162×409×
2018165×151×366×
2017n/m a value too high to mean anything
2016356×230×356×
2015336×333×471×

Against its peers

Companies in Medical - Devices nearest DexCom's size, closest first, today.

CompanyPrice to free cash flow
DXCMDexCom22.7×
GEHCGE HealthCare Technologies22.8×
EWEdwards Lifesciences38.1×
ZBHZimmer Biomet12.2×
BSXBoston Scientific17.4×
SYKStryker25.2×
MDTMedtronic20.7×
ABTAbbott Laboratoriesn/m
LIVNLivaNova29.8×
ITGRInteger52.6×
Peer median24.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on DexCom

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.